We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Alexion Recalls More Soliris Due to Persistent Particle Problem

Alexion Recalls More Soliris Due to Persistent Particle Problem

June 6, 2014

Alexion is pulling more of its flagship product Soliris from the market due to visible particles that arose from a manufacturing problem, its third recall in less than a year.

The drugmaker voluntarily recalled nine lots of the rare blood disease drug after visible protein particles were discovered in a single lot during periodic stability testing, the company said.

The move follows a voluntary recall announced in November 2013 and another in August 2013 due to a similar particulate problem. While the particles were discovered in one lot, Alexion is recalling the other eight because they were made using the same process component during vial filling that was the culprit of earlier recalls, the company said.

“Alexion believes it has identified the process component that result in the presence of the visible particles and implemented a change to the process,” it noted.

The drugmaker declined to elaborate on specifics, but noted the problems were tied to a third-party contractor, one of three used by the drugmaker. “We replaced the single process step with this one third-party vial filler,” Alexion spokeswoman Kim Diamond said.

Alexion hasn’t received any adverse safety reports from the product. But it stressed that particulate in a parenteral drug could block the flow of blood in vessels, which could lead to life-threatening blood clots. The particulates also could create an immune reaction.

The company said it doesn’t anticipate any supply disruptions due to the recall. The drug, which is Alexion’s only approved product, treats the rare blood disease paroxysmal nocturnal hemoglobinuria and genetic disease atypical hemolytic uremic syndrome, Diamond said the company expects that the current and prior Soliris recalls will cost the company between $10 and $25 million.

Don’t let this happen to you, prevent contamination by purchasing Manufacturing Sterile Products to Meet EU and FDA Guidelines.

Pharmaceuticals Quality GMPs Commercial Operations

Upcoming Events

  • 19Jan

    Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management

  • 21Jan

    Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Regeneron logo

    U.S. Government Orders More Supplies of Regeneron’s COVID-19 Antibody Cocktail

  • Siemens Healthineers logo

    Siemens Healthineers COVID Test Gets Additional Sampling Method Clearance

  • COVID-19  Clinical Trial

    Synairgen Initiates Dosing in Late-Stage Trial of Inhaled COVID-19 Therapy

  • Verona Pharma logo

    Verona Pharma Ends Enrollment in Inhaler-Administered COVID-19 Drug Pilot

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing